| Expression pattern: |
DN |
| Associated gene: |
TDP-43, cGAS, STING |
| Associated microRNA: |
- |
| Biological function: |
Induces immunogenic cell death, promotes antitumor immunity, enhances response to anti-PD-1 therapy, and induces tumor-specific immunologic memory in lung adenocarcinoma models. |
| Molecular mechanism: |
cEMSY binds the RBP TDP-43 (via RRM1), promotes its mitochondrial aggregation, triggers mtDNA leakage to cytosol, activates cGAS-STING antiviral signaling, leading to ICD and immune activation. |
| Biological pathway or process: |
STING/IFN (promotes); immune regulation (promotes); metastasis (inhibits); apoptosis (other); ceRNA regulation (other) |
| Detected method: |
Q
H
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; RNA-seq; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Western Blot; Transfection; Flow Cytometry（Non-apoptosis/cycle）; ELISA; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); IF (Immunofluorescence); Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Elevated cEMSY expression correlates with increased dendritic cell and CD8+ T-cell infiltration and favorable immunotherapy response; higher cEMSY expression associates with prolonged disease-free survival in LUAD. |
| Description: |
cEMSY is down-regulated in lung adenocarcinoma tissues and cells and functions as an immunogenic ICD inducer. It binds TDP-43 (RRM1-dependent) to promote mitochondrial TDP-43 aggregation, mtDNA leakage, and cGAS-STING activation, thereby enhancing antitumor immunity and sensitizing tumors to anti-PD-1 therapy, with favorable clinical immunotherapy response associations. |
| Confidence score: |
0.8792 |